As it search­es for a new CEO, Il­lu­mi­na faces a high-stakes year of chal­lenges

Just two and a half weeks af­ter the abrupt ex­it of Il­lu­mi­na’s CEO Fran­cis deS­ouza, the DNA se­quenc­ing gi­ant is fac­ing one of the most piv­otal pe­ri­ods in its his­to­ry.

It has promised in­vestors $100 mil­lion in cost cuts, is await­ing the fi­nal out­come in an an­titrust saga stem­ming from its $7.1 bil­lion ac­qui­si­tion of can­cer test de­vel­op­er Grail, and faces com­pe­ti­tion that wasn’t there a few years ago. This all comes amid its search for a new CEO, who will have to lead the San Diego-based com­pa­ny through those dif­fi­cul­ties.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA